

# Vito G D'agostino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8798369/publications.pdf>

Version: 2024-02-01

34  
papers

1,355  
citations

361296

20  
h-index

395590

33  
g-index

36  
all docs

36  
docs citations

36  
times ranked

3027  
citing authors

#	ARTICLE	IF	CITATIONS
1	C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation. <i>EMBO Journal</i> , 2022, 41, e105026.	3.5	13
2	Zebrafish Melanoma-Derived Interstitial EVs Are Carriers of ncRNAs That Induce Inflammation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5510.	1.8	3
3	Expression of Cellular and Extracellular TERRA, TERC and TERT in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6183.	1.8	15
4	Identification and Characterization of an RRM-Containing, RNA Binding Protein in <i>Acinetobacter baumannii</i> . <i>Biomolecules</i> , 2022, 12, 922.	1.8	0
5	Enzymatically active apurinic/apyrimidinic endodeoxyribonuclease 1 is released by mammalian cells through exosomes. <i>Journal of Biological Chemistry</i> , 2021, 296, 100569.	1.6	18
6	Unveiling mutational dynamics in non-small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA. <i>Molecular Oncology</i> , 2021, 15, 2423-2438.	2.1	10
7	Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. <i>Molecular Neurodegeneration</i> , 2021, 16, 52.	4.4	19
8	RNA packaging into extracellular vesicles: An orchestra of RNA-binding proteins?. <i>Journal of Extracellular Vesicles</i> , 2020, 10, e12043.	5.5	135
9	Rapid Nickel-based Isolation of Extracellular Vesicles from Different Biological Fluids. <i>Bio-protocol</i> , 2020, 10, e3512.	0.2	7
10	Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). <i>BMJ Open</i> , 2019, 9, e028486.	0.8	44
11	Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood. <i>EBioMedicine</i> , 2019, 43, 114-126.	2.7	40
12	Tristetraprolin/ZFP36 Regulates the Turnover of Autoimmune-Associated HLA-DQ mRNAs. <i>Cells</i> , 2019, 8, 1570.	1.8	6
13	Screening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery. <i>SLAS Discovery</i> , 2019, 24, 314-331.	1.4	29
14	Interfering with HuR-RNA Interaction: Design, Synthesis and Biological Characterization of Tanshinone Mimics as Novel, Effective HuR Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1483-1498.	2.9	39
15	Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA. <i>Cancer &amp; Metabolism</i> , 2018, 6, 1.	2.4	29
16	Structural Analysis of Small-Molecule Binding to the BAZ2A and BAZ2B Bromodomains. <i>ChemMedChem</i> , 2018, 13, 1479-1487.	1.6	11
17	HuD Is a Neural Translation Enhancer Acting on mTORC1-Responsive Genes and Counteracted by the Y3 Small Non-coding RNA. <i>Molecular Cell</i> , 2018, 71, 256-270.e10.	4.5	51
18	Regulation of HuR structure and function by dihydrotanshinone-I. <i>Nucleic Acids Research</i> , 2017, 45, 9514-9527.	6.5	64

#	ARTICLE	IF	CITATIONS
19	Transcriptional induction of the heat shock protein B8 mediates the clearance of misfolded proteins responsible for motor neuron diseases. <i>Scientific Reports</i> , 2016, 6, 22827.	1.6	78
20	The Ribonucleic Complex HuR-MALAT1 Represses CD133 Expression and Suppresses Epithelial to Mesenchymal Transition in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2626-2636.	0.4	113
21	JNK1 ablation in mice confers long-term metabolic protection from diet-induced obesity at the cost of moderate skin oxidative damage. <i>FASEB Journal</i> , 2016, 30, 3124-3132.	0.2	11
22	Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction. <i>Oncotarget</i> , 2016, 7, 84810-84825.	0.8	20
23	The GSK3 $\beta$ inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level. <i>Oncotarget</i> , 2016, 7, 26551-26566.	0.8	18
24	EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition. <i>BMC Cancer</i> , 2015, 15, 855.	1.1	13
25	Dihydratanshinone-I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function. <i>Scientific Reports</i> , 2015, 5, 16478.	1.6	65
26	Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition. <i>Oncotarget</i> , 2015, 6, 11820-11832.	0.8	67
27	Targeting the Multifaceted HuR Protein, Benefits and Caveats. <i>Current Drug Targets</i> , 2015, 16, 499-515.	1.0	61
28	Nicotinamide Phosphoribosyltransferase Promotes Epithelial-to-Mesenchymal Transition as a Soluble Factor Independent of Its Enzymatic Activity. <i>Journal of Biological Chemistry</i> , 2014, 289, 34189-34204.	1.6	64
29	A Novel High Throughput Biochemical Assay to Evaluate the HuR Protein-RNA Complex Formation. <i>PLoS ONE</i> , 2013, 8, e72426.	1.1	57
30	Autophagy Activation Clears ELAVL1/HuR-Mediated Accumulation of SQSTM1/p62 during Proteasomal Inhibition in Human Retinal Pigment Epithelial Cells. <i>PLoS ONE</i> , 2013, 8, e69563.	1.1	138
31	MUTYH-associated polyposis (MAP), the syndrome implicating base excision repair in inherited predisposition to colorectal tumors. <i>Frontiers in Oncology</i> , 2012, 2, 83.	1.3	17
32	Functional analysis of MUTYH mutated proteins associated with familial adenomatous polyposis. <i>DNA Repair</i> , 2010, 9, 700-707.	1.3	39
33	MUTYH mutations associated with familial adenomatous polyposis: functional characterization by a mammalian cell-based assay. <i>Human Mutation</i> , 2010, 31, 159-166.	1.1	41
34	The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. <i>BMC Medical Genomics</i> , 2009, 2, 20.	0.7	20